Free audio stream, including stories that are padlocked on our site. Listen on any device, anywhere. Updated twice daily. The audio stream takes several seconds to start on Android devices.Launch Radio player
Pacific Edge plans to open its first US franchise to market the company’s bladder cancer detection test, Cxbladder, to urologists in the United States by the end of the year.
The Dunedin-based firm will set up shop at the Hershey Center for Applied Research (HCAR) on America’s East Coast.
The 11,348 square-foot Pacific Edge facility will serve as an office and processing facility for the analysis of the Cxbladder test – which utilises the expression of genes in the patients’ urine to detect the presence of bladder cancer accurately and non-invasively.
Planning and construction for the new facility is currently underway and will involve about 100 new employees over the next three year.
“It’s a huge opportunity to be in the US market,” says David Darling, CEO of Pacific Edge, “It’s probably the biggest prize in the world when it comes to a responsive healthcare market that really understands what molecular diagnostics can do in a clinical setting.”
Pacific Edge has been scoping potential marketing opportunities for some time.
“As part of our business development process we met the people from HCAR in Europe at a business partnering forum, where we were looking for opportunities and various reasons in the United States to see where we should be best located strategically,” Mr Darling says.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- Key sending in 'Mr Fix-it' to hurry Brownlee along?
- Briefcase: A tale of two firms, and the rise of the salaried partner
- ComCom proposes to let telco retailers keep $57 million
- Briscoe's bid below par, say analysts as Kathmandu says take no action
- Government guidelines give green light to industrial-scale counterfeiting